Engineered Tissue Solutions Announces AJ Ford as New CEO
Ford’s appointment comes as existing CEO Dr. Nicolas Guggenheim retires
Rolla, MO, June 10, 2024 – Engineered Tissue Solutions (ETS), a leader in innovative wound care solutions, is pleased to welcome AJ Ford as the new Chief Executive Officer. Ford brings over 13 years of experience in the medical device industry with a heavy emphasis on competitive strategy, sales and marketing, clinical evidence planning, and new product development. He will be replacing Dr. Nicolas Guggenheim, who is retiring.
Dr. Guggenheim has created and developed multiple medical device businesses over his career. Most recently, he has successfully supported the growth and development of ETS and is proud to hand it over to AJ Ford.
AJ holds a Bachelor of Science in Biomedical Engineering from Washington University in St. Louis and dual Master’s degrees in Biomedical Engineering and Engineering Management from Duke University. Throughout his career, AJ has held influential leadership roles at Medline, where he excelled in product management within the advanced wound care and tissue regeneration divisions. Most recently, he served as Vice President of Sales for the Skin Health team, where he successfully launched new products and developed comprehensive marketing, sales, and competitive strategies.
Ford’s introduction comes as ETS disrupts the tissue regeneration space with the Mirragen® bioactive glass wound matrix, an innovative skin substitute (also referred to as CTPs or CAMPs within the industry) designed to conform to any wound bed. Mirragen has demonstrated impressive clinical results across a broad spectrum of wounds — from chronic ulcers to complex surgical deficits — showcasing its versatility and effectiveness in wound care.
“We are incredibly passionate about creating and commercializing novel technologies that help providers and their patients overcome the myriad challenges faced in wound care today,” says AJ.
As he steps into his new role, he also conveys a strong message of commitment to both ETS employees and customers. “Fostering strong relationships with all stakeholders is key for ETS’s long-term success. The company is deeply invested in its groundbreaking, borate-based bioactive glass as a platform technology in wound care, and we are dedicated to continuing to promote and prove the efficacy of our products through robust technical and clinical evidence.”
###
About Engineered Tissue Solutions (ETS): Engineered Tissue Solutions (ETS) is an innovative company in the medical device industry, dedicated to advancing wound healing through cutting-edge borate-based bioactive glass technology. As a member of the Heraeus Group, a globally diversified family-owned technology company, ETS draws upon a legacy of excellence and innovation. Learn more about the Heraeus Group at www.Heraeus.com.